Sensei Biotherapeutics Announces Initiation Of Combination Arm For Phase 1/2 Clinical Study Of SNS-101 With Regeneron's Libtayo
Author: Benzinga Newsdesk | September 27, 2023 07:32am
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
Posted In: SNSE